Wezenla

Wezenla (ustekinumab) is a prescription biologic used to treat moderate to severe plaque psoriasis and psoriatic arthritis. This subcutaneous injection helps manage symptoms like skin plaques and joint inflammation. Always consult a healthcare provider before use.

Wezenla (ustekinumab) is prescribed for adults and children with moderate to severe plaque psoriasis, a condition causing thick, red, scaly patches on the skin. It is also used to treat active psoriatic arthritis, which involves joint pain and swelling alongside skin symptoms. This medication works by targeting specific proteins in the immune system to reduce inflammation.

After administration, Wezenla (ustekinumab) may help reduce redness, scaling, and thickness of skin plaques associated with psoriasis. For psoriatic arthritis, it may ease joint pain and swelling, improving mobility. Individual responses vary, and visible improvements may take several weeks to appear.

Store Wezenla (ustekinumab) in the refrigerator between 2°C and 8°C (36°F and 46°F) and protect it from light. Do not freeze or shake the prefilled syringe or vial. Keep the medication out of reach of children. Discard any unused portion as directed by a healthcare professional.

Wezenla (ustekinumab) may interact with live vaccines, increasing the risk of infection. Avoid receiving live vaccines while using this medication. Inform your doctor about all medications, including over-the-counter drugs and supplements, to assess potential interactions before starting treatment.